nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—PTGS2—urinary bladder cancer	0.452	1	CbGaD
Triamcinolone—BCHE—Cisplatin—urinary bladder cancer	0.088	0.301	CbGbCtD
Triamcinolone—PTGS2—Cisplatin—urinary bladder cancer	0.0677	0.231	CbGbCtD
Triamcinolone—PTGS2—Etoposide—urinary bladder cancer	0.0666	0.227	CbGbCtD
Triamcinolone—CYP3A4—Thiotepa—urinary bladder cancer	0.0485	0.166	CbGbCtD
Triamcinolone—CYP3A4—Etoposide—urinary bladder cancer	0.0132	0.0449	CbGbCtD
Triamcinolone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00897	0.0306	CbGbCtD
Triamcinolone—NR3C1—urine—urinary bladder cancer	0.00376	0.115	CbGeAlD
Triamcinolone—CYP3A4—urine—urinary bladder cancer	0.00285	0.087	CbGeAlD
Triamcinolone—SERPINA6—renal system—urinary bladder cancer	0.0021	0.0643	CbGeAlD
Triamcinolone—SERPINA6—female reproductive system—urinary bladder cancer	0.00168	0.0515	CbGeAlD
Triamcinolone—BCHE—prostate gland—urinary bladder cancer	0.00152	0.0464	CbGeAlD
Triamcinolone—NR3C1—prostate gland—urinary bladder cancer	0.00135	0.0413	CbGeAlD
Triamcinolone—BCHE—seminal vesicle—urinary bladder cancer	0.00128	0.0393	CbGeAlD
Triamcinolone—PTGS2—prostate gland—urinary bladder cancer	0.00117	0.0358	CbGeAlD
Triamcinolone—NR3C1—seminal vesicle—urinary bladder cancer	0.00114	0.0349	CbGeAlD
Triamcinolone—BCHE—smooth muscle tissue—urinary bladder cancer	0.00107	0.0329	CbGeAlD
Triamcinolone—NR3C1—epithelium—urinary bladder cancer	0.000993	0.0304	CbGeAlD
Triamcinolone—PTGS2—seminal vesicle—urinary bladder cancer	0.000989	0.0302	CbGeAlD
Triamcinolone—NR3C1—smooth muscle tissue—urinary bladder cancer	0.000956	0.0293	CbGeAlD
Triamcinolone—NR3C1—renal system—urinary bladder cancer	0.000921	0.0282	CbGeAlD
Triamcinolone—NR3C1—urethra—urinary bladder cancer	0.000904	0.0277	CbGeAlD
Triamcinolone—PTGS2—epithelium—urinary bladder cancer	0.000859	0.0263	CbGeAlD
Triamcinolone—BCHE—female reproductive system—urinary bladder cancer	0.000828	0.0253	CbGeAlD
Triamcinolone—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000828	0.0253	CbGeAlD
Triamcinolone—PTGS2—renal system—urinary bladder cancer	0.000797	0.0244	CbGeAlD
Triamcinolone—PTGS2—urethra—urinary bladder cancer	0.000783	0.0239	CbGeAlD
Triamcinolone—BCHE—vagina—urinary bladder cancer	0.000749	0.0229	CbGeAlD
Triamcinolone—NR3C1—female reproductive system—urinary bladder cancer	0.000737	0.0226	CbGeAlD
Triamcinolone—CYP3A4—renal system—urinary bladder cancer	0.000696	0.0213	CbGeAlD
Triamcinolone—NR3C1—vagina—urinary bladder cancer	0.000667	0.0204	CbGeAlD
Triamcinolone—PTGS2—female reproductive system—urinary bladder cancer	0.000638	0.0195	CbGeAlD
Triamcinolone—PTGS2—vagina—urinary bladder cancer	0.000577	0.0177	CbGeAlD
Triamcinolone—CYP3A4—female reproductive system—urinary bladder cancer	0.000558	0.0171	CbGeAlD
Triamcinolone—BCHE—lymph node—urinary bladder cancer	0.000485	0.0148	CbGeAlD
Triamcinolone—NR3C1—lymph node—urinary bladder cancer	0.000431	0.0132	CbGeAlD
Triamcinolone—PTGS2—lymph node—urinary bladder cancer	0.000373	0.0114	CbGeAlD
Triamcinolone—Increased appetite—Doxorubicin—urinary bladder cancer	0.000214	0.00115	CcSEcCtD
Triamcinolone—Affect lability—Epirubicin—urinary bladder cancer	0.000214	0.00114	CcSEcCtD
Triamcinolone—Urticaria—Thiotepa—urinary bladder cancer	0.00021	0.00113	CcSEcCtD
Triamcinolone—Malaise—Etoposide—urinary bladder cancer	0.00021	0.00113	CcSEcCtD
Triamcinolone—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00021	0.00113	CcSEcCtD
Triamcinolone—Vertigo—Etoposide—urinary bladder cancer	0.00021	0.00112	CcSEcCtD
Triamcinolone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000209	0.00112	CcSEcCtD
Triamcinolone—Purpura—Doxorubicin—urinary bladder cancer	0.000208	0.00112	CcSEcCtD
Triamcinolone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000208	0.00111	CcSEcCtD
Triamcinolone—Oedema—Cisplatin—urinary bladder cancer	0.000208	0.00111	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000207	0.00111	CcSEcCtD
Triamcinolone—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000206	0.00111	CcSEcCtD
Triamcinolone—Infection—Cisplatin—urinary bladder cancer	0.000206	0.00111	CcSEcCtD
Triamcinolone—Mood swings—Epirubicin—urinary bladder cancer	0.000206	0.0011	CcSEcCtD
Triamcinolone—Loss of consciousness—Etoposide—urinary bladder cancer	0.000205	0.0011	CcSEcCtD
Triamcinolone—Cough—Etoposide—urinary bladder cancer	0.000203	0.00109	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000203	0.00109	CcSEcCtD
Triamcinolone—Tachycardia—Cisplatin—urinary bladder cancer	0.000203	0.00109	CcSEcCtD
Triamcinolone—Convulsion—Etoposide—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Triamcinolone—Insomnia—Gemcitabine—urinary bladder cancer	0.000202	0.00108	CcSEcCtD
Triamcinolone—Hypertension—Etoposide—urinary bladder cancer	0.000201	0.00108	CcSEcCtD
Triamcinolone—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000201	0.00108	CcSEcCtD
Triamcinolone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000201	0.00108	CcSEcCtD
Triamcinolone—Asthma—Methotrexate—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Triamcinolone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.0002	0.00107	CcSEcCtD
Triamcinolone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000199	0.00106	CcSEcCtD
Triamcinolone—Insomnia—Fluorouracil—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Triamcinolone—Affect lability—Doxorubicin—urinary bladder cancer	0.000198	0.00106	CcSEcCtD
Triamcinolone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000197	0.00105	CcSEcCtD
Triamcinolone—Pancreatitis—Methotrexate—urinary bladder cancer	0.000197	0.00105	CcSEcCtD
Triamcinolone—Discomfort—Etoposide—urinary bladder cancer	0.000196	0.00105	CcSEcCtD
Triamcinolone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000195	0.00105	CcSEcCtD
Triamcinolone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000195	0.00105	CcSEcCtD
Triamcinolone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000193	0.00103	CcSEcCtD
Triamcinolone—Fatigue—Gemcitabine—urinary bladder cancer	0.000192	0.00103	CcSEcCtD
Triamcinolone—Muscular weakness—Epirubicin—urinary bladder cancer	0.000191	0.00103	CcSEcCtD
Triamcinolone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000191	0.00102	CcSEcCtD
Triamcinolone—Pain—Gemcitabine—urinary bladder cancer	0.000191	0.00102	CcSEcCtD
Triamcinolone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00019	0.00102	CcSEcCtD
Triamcinolone—Mood swings—Doxorubicin—urinary bladder cancer	0.00019	0.00102	CcSEcCtD
Triamcinolone—Asthenia—Thiotepa—urinary bladder cancer	0.00019	0.00102	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Triamcinolone—Infection—Etoposide—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Triamcinolone—Abdominal distension—Epirubicin—urinary bladder cancer	0.000189	0.00101	CcSEcCtD
Triamcinolone—Influenza—Epirubicin—urinary bladder cancer	0.000188	0.00101	CcSEcCtD
Triamcinolone—Asthma—Epirubicin—urinary bladder cancer	0.000188	0.00101	CcSEcCtD
Triamcinolone—Pruritus—Thiotepa—urinary bladder cancer	0.000187	0.001	CcSEcCtD
Triamcinolone—Pain—Fluorouracil—urinary bladder cancer	0.000187	0.001	CcSEcCtD
Triamcinolone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000187	0.001	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000186	0.000998	CcSEcCtD
Triamcinolone—Tachycardia—Etoposide—urinary bladder cancer	0.000186	0.000995	CcSEcCtD
Triamcinolone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000185	0.000992	CcSEcCtD
Triamcinolone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000184	0.000986	CcSEcCtD
Triamcinolone—Pancreatitis—Epirubicin—urinary bladder cancer	0.000184	0.000986	CcSEcCtD
Triamcinolone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000184	0.000984	CcSEcCtD
Triamcinolone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000181	0.000968	CcSEcCtD
Triamcinolone—Bronchitis—Epirubicin—urinary bladder cancer	0.00018	0.000967	CcSEcCtD
Triamcinolone—Pain—Cisplatin—urinary bladder cancer	0.000178	0.000952	CcSEcCtD
Triamcinolone—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000177	0.000949	CcSEcCtD
Triamcinolone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000176	0.000944	CcSEcCtD
Triamcinolone—Dizziness—Thiotepa—urinary bladder cancer	0.000175	0.000939	CcSEcCtD
Triamcinolone—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000175	0.000936	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000174	0.000934	CcSEcCtD
Triamcinolone—Urticaria—Fluorouracil—urinary bladder cancer	0.000174	0.000933	CcSEcCtD
Triamcinolone—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000174	0.000931	CcSEcCtD
Triamcinolone—Asthma—Doxorubicin—urinary bladder cancer	0.000174	0.00093	CcSEcCtD
Triamcinolone—Influenza—Doxorubicin—urinary bladder cancer	0.000174	0.00093	CcSEcCtD
Triamcinolone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000173	0.000928	CcSEcCtD
Triamcinolone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000171	0.000917	CcSEcCtD
Triamcinolone—Paraesthesia—Etoposide—urinary bladder cancer	0.000171	0.000916	CcSEcCtD
Triamcinolone—Weight increased—Epirubicin—urinary bladder cancer	0.000171	0.000915	CcSEcCtD
Triamcinolone—Pancreatitis—Doxorubicin—urinary bladder cancer	0.00017	0.000912	CcSEcCtD
Triamcinolone—Dyspnoea—Etoposide—urinary bladder cancer	0.00017	0.000909	CcSEcCtD
Triamcinolone—Epistaxis—Methotrexate—urinary bladder cancer	0.000169	0.000903	CcSEcCtD
Triamcinolone—Vomiting—Thiotepa—urinary bladder cancer	0.000168	0.000903	CcSEcCtD
Triamcinolone—Rash—Thiotepa—urinary bladder cancer	0.000167	0.000895	CcSEcCtD
Triamcinolone—Bronchitis—Doxorubicin—urinary bladder cancer	0.000167	0.000895	CcSEcCtD
Triamcinolone—Dermatitis—Thiotepa—urinary bladder cancer	0.000167	0.000894	CcSEcCtD
Triamcinolone—Headache—Thiotepa—urinary bladder cancer	0.000166	0.000889	CcSEcCtD
Triamcinolone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000164	0.00088	CcSEcCtD
Triamcinolone—Fatigue—Etoposide—urinary bladder cancer	0.000164	0.000879	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000164	0.000879	CcSEcCtD
Triamcinolone—Pain—Etoposide—urinary bladder cancer	0.000163	0.000872	CcSEcCtD
Triamcinolone—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000163	0.000871	CcSEcCtD
Triamcinolone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000161	0.000865	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000161	0.000865	CcSEcCtD
Triamcinolone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000161	0.000864	CcSEcCtD
Triamcinolone—Haemorrhage—Methotrexate—urinary bladder cancer	0.00016	0.00086	CcSEcCtD
Triamcinolone—Asthenia—Gemcitabine—urinary bladder cancer	0.00016	0.000857	CcSEcCtD
Triamcinolone—Pharyngitis—Methotrexate—urinary bladder cancer	0.000159	0.000853	CcSEcCtD
Triamcinolone—Weight increased—Doxorubicin—urinary bladder cancer	0.000158	0.000847	CcSEcCtD
Triamcinolone—Epistaxis—Epirubicin—urinary bladder cancer	0.000158	0.000845	CcSEcCtD
Triamcinolone—Pruritus—Gemcitabine—urinary bladder cancer	0.000158	0.000845	CcSEcCtD
Triamcinolone—Nausea—Thiotepa—urinary bladder cancer	0.000157	0.000843	CcSEcCtD
Triamcinolone—Feeling abnormal—Etoposide—urinary bladder cancer	0.000157	0.00084	CcSEcCtD
Triamcinolone—Pruritus—Fluorouracil—urinary bladder cancer	0.000155	0.000831	CcSEcCtD
Triamcinolone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000153	0.00082	CcSEcCtD
Triamcinolone—Bradycardia—Epirubicin—urinary bladder cancer	0.000153	0.000819	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000152	0.000813	CcSEcCtD
Triamcinolone—Urticaria—Etoposide—urinary bladder cancer	0.000151	0.00081	CcSEcCtD
Triamcinolone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000151	0.000809	CcSEcCtD
Triamcinolone—Rhinitis—Epirubicin—urinary bladder cancer	0.000151	0.000807	CcSEcCtD
Triamcinolone—Body temperature increased—Etoposide—urinary bladder cancer	0.00015	0.000806	CcSEcCtD
Triamcinolone—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.00015	0.000806	CcSEcCtD
Triamcinolone—Haemorrhage—Epirubicin—urinary bladder cancer	0.00015	0.000805	CcSEcCtD
Triamcinolone—Asthenia—Cisplatin—urinary bladder cancer	0.000149	0.000799	CcSEcCtD
Triamcinolone—Pharyngitis—Epirubicin—urinary bladder cancer	0.000149	0.000799	CcSEcCtD
Triamcinolone—Epistaxis—Doxorubicin—urinary bladder cancer	0.000146	0.000782	CcSEcCtD
Triamcinolone—Dizziness—Fluorouracil—urinary bladder cancer	0.000145	0.000777	CcSEcCtD
Triamcinolone—Vomiting—Gemcitabine—urinary bladder cancer	0.000142	0.000759	CcSEcCtD
Triamcinolone—Bradycardia—Doxorubicin—urinary bladder cancer	0.000141	0.000758	CcSEcCtD
Triamcinolone—Rash—Gemcitabine—urinary bladder cancer	0.000141	0.000753	CcSEcCtD
Triamcinolone—Dermatitis—Gemcitabine—urinary bladder cancer	0.00014	0.000752	CcSEcCtD
Triamcinolone—Hypersensitivity—Etoposide—urinary bladder cancer	0.00014	0.000751	CcSEcCtD
Triamcinolone—Erythema—Methotrexate—urinary bladder cancer	0.00014	0.000749	CcSEcCtD
Triamcinolone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00014	0.000748	CcSEcCtD
Triamcinolone—Headache—Gemcitabine—urinary bladder cancer	0.00014	0.000748	CcSEcCtD
Triamcinolone—Vomiting—Fluorouracil—urinary bladder cancer	0.000139	0.000747	CcSEcCtD
Triamcinolone—Rhinitis—Doxorubicin—urinary bladder cancer	0.000139	0.000746	CcSEcCtD
Triamcinolone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000139	0.000745	CcSEcCtD
Triamcinolone—Rash—Fluorouracil—urinary bladder cancer	0.000138	0.00074	CcSEcCtD
Triamcinolone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000138	0.00074	CcSEcCtD
Triamcinolone—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000138	0.000739	CcSEcCtD
Triamcinolone—Headache—Fluorouracil—urinary bladder cancer	0.000137	0.000736	CcSEcCtD
Triamcinolone—Dysgeusia—Methotrexate—urinary bladder cancer	0.000137	0.000733	CcSEcCtD
Triamcinolone—Asthenia—Etoposide—urinary bladder cancer	0.000137	0.000732	CcSEcCtD
Triamcinolone—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000136	0.00384	CbGpPWpGaD
Triamcinolone—Back pain—Methotrexate—urinary bladder cancer	0.000135	0.000724	CcSEcCtD
Triamcinolone—Pruritus—Etoposide—urinary bladder cancer	0.000135	0.000722	CcSEcCtD
Triamcinolone—Arrhythmia—Epirubicin—urinary bladder cancer	0.000134	0.000719	CcSEcCtD
Triamcinolone—BCHE—Peptide hormone metabolism—IGF1—urinary bladder cancer	0.000134	0.00376	CbGpPWpGaD
Triamcinolone—Nausea—Gemcitabine—urinary bladder cancer	0.000132	0.000709	CcSEcCtD
Triamcinolone—Vomiting—Cisplatin—urinary bladder cancer	0.000132	0.000708	CcSEcCtD
Triamcinolone—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000132	0.00371	CbGpPWpGaD
Triamcinolone—Rash—Cisplatin—urinary bladder cancer	0.000131	0.000702	CcSEcCtD
Triamcinolone—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000131	0.00368	CbGpPWpGaD
Triamcinolone—Dermatitis—Cisplatin—urinary bladder cancer	0.000131	0.000701	CcSEcCtD
Triamcinolone—Erythema—Epirubicin—urinary bladder cancer	0.000131	0.0007	CcSEcCtD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000131	0.00367	CbGpPWpGaD
Triamcinolone—Nausea—Fluorouracil—urinary bladder cancer	0.00013	0.000698	CcSEcCtD
Triamcinolone—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00013	0.000695	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000129	0.00363	CbGpPWpGaD
Triamcinolone—Dysgeusia—Epirubicin—urinary bladder cancer	0.000128	0.000686	CcSEcCtD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.000128	0.00359	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—NCOR1—urinary bladder cancer	0.000127	0.00357	CbGpPWpGaD
Triamcinolone—Back pain—Epirubicin—urinary bladder cancer	0.000126	0.000678	CcSEcCtD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—urinary bladder cancer	0.000126	0.00356	CbGpPWpGaD
Triamcinolone—Malaise—Methotrexate—urinary bladder cancer	0.000126	0.000675	CcSEcCtD
Triamcinolone—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000126	0.00354	CbGpPWpGaD
Triamcinolone—Dizziness—Etoposide—urinary bladder cancer	0.000126	0.000674	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—CDKN2A—urinary bladder cancer	0.000126	0.00353	CbGpPWpGaD
Triamcinolone—Vertigo—Methotrexate—urinary bladder cancer	0.000125	0.000672	CcSEcCtD
Triamcinolone—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000124	0.00349	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000124	0.00349	CbGpPWpGaD
Triamcinolone—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000124	0.000665	CcSEcCtD
Triamcinolone—Nausea—Cisplatin—urinary bladder cancer	0.000123	0.000661	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000122	0.00345	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of Androgen receptor activity—EP300—urinary bladder cancer	0.000122	0.00343	CbGpPWpGaD
Triamcinolone—Cough—Methotrexate—urinary bladder cancer	0.000122	0.000653	CcSEcCtD
Triamcinolone—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000121	0.00065	CcSEcCtD
Triamcinolone—Convulsion—Methotrexate—urinary bladder cancer	0.000121	0.000649	CcSEcCtD
Triamcinolone—Vomiting—Etoposide—urinary bladder cancer	0.000121	0.000648	CcSEcCtD
Triamcinolone—Erythema—Doxorubicin—urinary bladder cancer	0.000121	0.000648	CcSEcCtD
Triamcinolone—Rash—Etoposide—urinary bladder cancer	0.00012	0.000643	CcSEcCtD
Triamcinolone—Dermatitis—Etoposide—urinary bladder cancer	0.00012	0.000642	CcSEcCtD
Triamcinolone—Headache—Etoposide—urinary bladder cancer	0.000119	0.000639	CcSEcCtD
Triamcinolone—Myalgia—Methotrexate—urinary bladder cancer	0.000119	0.000637	CcSEcCtD
Triamcinolone—NR3C1—Regulation of Androgen receptor activity—SRC—urinary bladder cancer	0.000119	0.00334	CbGpPWpGaD
Triamcinolone—NR3C1—Circadian Clock—EP300—urinary bladder cancer	0.000118	0.00333	CbGpPWpGaD
Triamcinolone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000118	0.000635	CcSEcCtD
Triamcinolone—Malaise—Epirubicin—urinary bladder cancer	0.000118	0.000632	CcSEcCtD
Triamcinolone—Discomfort—Methotrexate—urinary bladder cancer	0.000117	0.00063	CcSEcCtD
Triamcinolone—Vertigo—Epirubicin—urinary bladder cancer	0.000117	0.000629	CcSEcCtD
Triamcinolone—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000117	0.0033	CbGpPWpGaD
Triamcinolone—Syncope—Epirubicin—urinary bladder cancer	0.000117	0.000628	CcSEcCtD
Triamcinolone—Back pain—Doxorubicin—urinary bladder cancer	0.000117	0.000627	CcSEcCtD
Triamcinolone—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000116	0.00327	CbGpPWpGaD
Triamcinolone—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000115	0.000616	CcSEcCtD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000114	0.00322	CbGpPWpGaD
Triamcinolone—Cough—Epirubicin—urinary bladder cancer	0.000114	0.000611	CcSEcCtD
Triamcinolone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000114	0.000611	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—CXCL8—urinary bladder cancer	0.000114	0.00321	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—FAS—urinary bladder cancer	0.000114	0.0032	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000114	0.0032	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000114	0.00319	CbGpPWpGaD
Triamcinolone—Convulsion—Epirubicin—urinary bladder cancer	0.000113	0.000607	CcSEcCtD
Triamcinolone—Infection—Methotrexate—urinary bladder cancer	0.000113	0.000607	CcSEcCtD
Triamcinolone—Nausea—Etoposide—urinary bladder cancer	0.000113	0.000606	CcSEcCtD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000113	0.00318	CbGpPWpGaD
Triamcinolone—Hypertension—Epirubicin—urinary bladder cancer	0.000113	0.000605	CcSEcCtD
Triamcinolone—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000112	0.000601	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000112	0.00315	CbGpPWpGaD
Triamcinolone—Myalgia—Epirubicin—urinary bladder cancer	0.000111	0.000596	CcSEcCtD
Triamcinolone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00011	0.000591	CcSEcCtD
Triamcinolone—Discomfort—Epirubicin—urinary bladder cancer	0.00011	0.000589	CcSEcCtD
Triamcinolone—Malaise—Doxorubicin—urinary bladder cancer	0.000109	0.000584	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—IL2—urinary bladder cancer	0.000109	0.00306	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000109	0.00306	CbGpPWpGaD
Triamcinolone—Dry mouth—Epirubicin—urinary bladder cancer	0.000109	0.000583	CcSEcCtD
Triamcinolone—Vertigo—Doxorubicin—urinary bladder cancer	0.000109	0.000582	CcSEcCtD
Triamcinolone—Syncope—Doxorubicin—urinary bladder cancer	0.000108	0.000581	CcSEcCtD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000108	0.00304	CbGpPWpGaD
Triamcinolone—Oedema—Epirubicin—urinary bladder cancer	0.000107	0.000572	CcSEcCtD
Triamcinolone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000107	0.000572	CcSEcCtD
Triamcinolone—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000106	0.00057	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—CCND1—urinary bladder cancer	0.000106	0.00299	CbGpPWpGaD
Triamcinolone—Infection—Epirubicin—urinary bladder cancer	0.000106	0.000568	CcSEcCtD
Triamcinolone—Cough—Doxorubicin—urinary bladder cancer	0.000106	0.000566	CcSEcCtD
Triamcinolone—Shock—Epirubicin—urinary bladder cancer	0.000105	0.000562	CcSEcCtD
Triamcinolone—Convulsion—Doxorubicin—urinary bladder cancer	0.000105	0.000562	CcSEcCtD
Triamcinolone—Hypertension—Doxorubicin—urinary bladder cancer	0.000104	0.00056	CcSEcCtD
Triamcinolone—Tachycardia—Epirubicin—urinary bladder cancer	0.000104	0.000558	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000104	0.000557	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000104	0.00291	CbGpPWpGaD
Triamcinolone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000103	0.000553	CcSEcCtD
Triamcinolone—Insomnia—Methotrexate—urinary bladder cancer	0.000103	0.000553	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—MMP9—urinary bladder cancer	0.000103	0.0029	CbGpPWpGaD
Triamcinolone—Myalgia—Doxorubicin—urinary bladder cancer	0.000103	0.000552	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—PTEN—urinary bladder cancer	0.000102	0.00288	CbGpPWpGaD
Triamcinolone—Paraesthesia—Methotrexate—urinary bladder cancer	0.000102	0.000549	CcSEcCtD
Triamcinolone—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000102	0.00288	CbGpPWpGaD
Triamcinolone—Discomfort—Doxorubicin—urinary bladder cancer	0.000102	0.000545	CcSEcCtD
Triamcinolone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000102	0.000545	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000101	0.00284	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000101	0.00283	CbGpPWpGaD
Triamcinolone—Dry mouth—Doxorubicin—urinary bladder cancer	0.000101	0.00054	CcSEcCtD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—urinary bladder cancer	0.0001	0.00282	CbGpPWpGaD
Triamcinolone—Dyspepsia—Methotrexate—urinary bladder cancer	0.0001	0.000538	CcSEcCtD
Triamcinolone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	9.87e-05	0.000529	CcSEcCtD
Triamcinolone—Oedema—Doxorubicin—urinary bladder cancer	9.87e-05	0.000529	CcSEcCtD
Triamcinolone—Fatigue—Methotrexate—urinary bladder cancer	9.83e-05	0.000527	CcSEcCtD
Triamcinolone—Infection—Doxorubicin—urinary bladder cancer	9.81e-05	0.000526	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—EP300—urinary bladder cancer	9.77e-05	0.00275	CbGpPWpGaD
Triamcinolone—Pain—Methotrexate—urinary bladder cancer	9.75e-05	0.000522	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.72e-05	0.000521	CcSEcCtD
Triamcinolone—Shock—Doxorubicin—urinary bladder cancer	9.71e-05	0.00052	CcSEcCtD
Triamcinolone—Insomnia—Epirubicin—urinary bladder cancer	9.65e-05	0.000517	CcSEcCtD
Triamcinolone—Tachycardia—Doxorubicin—urinary bladder cancer	9.63e-05	0.000516	CcSEcCtD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—IL2—urinary bladder cancer	9.59e-05	0.0027	CbGpPWpGaD
Triamcinolone—Paraesthesia—Epirubicin—urinary bladder cancer	9.58e-05	0.000513	CcSEcCtD
Triamcinolone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.54e-05	0.000511	CcSEcCtD
Triamcinolone—Dyspnoea—Epirubicin—urinary bladder cancer	9.51e-05	0.00051	CcSEcCtD
Triamcinolone—BCHE—Metabolism of proteins—CDX2—urinary bladder cancer	9.5e-05	0.00267	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	9.4e-05	0.00264	CbGpPWpGaD
Triamcinolone—Feeling abnormal—Methotrexate—urinary bladder cancer	9.39e-05	0.000503	CcSEcCtD
Triamcinolone—Dyspepsia—Epirubicin—urinary bladder cancer	9.39e-05	0.000503	CcSEcCtD
Triamcinolone—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	9.22e-05	0.0026	CbGpPWpGaD
Triamcinolone—Fatigue—Epirubicin—urinary bladder cancer	9.2e-05	0.000493	CcSEcCtD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	9.16e-05	0.00258	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	9.14e-05	0.00257	CbGpPWpGaD
Triamcinolone—Pain—Epirubicin—urinary bladder cancer	9.12e-05	0.000489	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—PPARG—urinary bladder cancer	9.1e-05	0.00256	CbGpPWpGaD
Triamcinolone—Urticaria—Methotrexate—urinary bladder cancer	9.06e-05	0.000485	CcSEcCtD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—urinary bladder cancer	9.05e-05	0.00255	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	9.03e-05	0.00254	CbGpPWpGaD
Triamcinolone—Body temperature increased—Methotrexate—urinary bladder cancer	9.01e-05	0.000483	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	8.99e-05	0.000482	CcSEcCtD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.99e-05	0.00253	CbGpPWpGaD
Triamcinolone—Insomnia—Doxorubicin—urinary bladder cancer	8.93e-05	0.000478	CcSEcCtD
Triamcinolone—Paraesthesia—Doxorubicin—urinary bladder cancer	8.86e-05	0.000475	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	8.83e-05	0.00248	CbGpPWpGaD
Triamcinolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	8.81e-05	0.00248	CbGpPWpGaD
Triamcinolone—Dyspnoea—Doxorubicin—urinary bladder cancer	8.8e-05	0.000472	CcSEcCtD
Triamcinolone—Feeling abnormal—Epirubicin—urinary bladder cancer	8.79e-05	0.000471	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—RB1—urinary bladder cancer	8.71e-05	0.00245	CbGpPWpGaD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	8.69e-05	0.00245	CbGpPWpGaD
Triamcinolone—Dyspepsia—Doxorubicin—urinary bladder cancer	8.69e-05	0.000466	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—IGF1—urinary bladder cancer	8.63e-05	0.00243	CbGpPWpGaD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—EP300—urinary bladder cancer	8.61e-05	0.00242	CbGpPWpGaD
Triamcinolone—NR3C1—AP-1 transcription factor network—MYC—urinary bladder cancer	8.51e-05	0.0024	CbGpPWpGaD
Triamcinolone—Fatigue—Doxorubicin—urinary bladder cancer	8.51e-05	0.000456	CcSEcCtD
Triamcinolone—Urticaria—Epirubicin—urinary bladder cancer	8.47e-05	0.000454	CcSEcCtD
Triamcinolone—Pain—Doxorubicin—urinary bladder cancer	8.44e-05	0.000452	CcSEcCtD
Triamcinolone—Body temperature increased—Epirubicin—urinary bladder cancer	8.43e-05	0.000452	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	8.41e-05	0.00237	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Methotrexate—urinary bladder cancer	8.4e-05	0.00045	CcSEcCtD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	8.34e-05	0.00235	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	8.23e-05	0.00232	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	8.2e-05	0.00231	CbGpPWpGaD
Triamcinolone—Asthenia—Methotrexate—urinary bladder cancer	8.18e-05	0.000438	CcSEcCtD
Triamcinolone—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.13e-05	0.000436	CcSEcCtD
Triamcinolone—Pruritus—Methotrexate—urinary bladder cancer	8.06e-05	0.000432	CcSEcCtD
Triamcinolone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	7.87e-05	0.00221	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Epirubicin—urinary bladder cancer	7.86e-05	0.000421	CcSEcCtD
Triamcinolone—Urticaria—Doxorubicin—urinary bladder cancer	7.84e-05	0.00042	CcSEcCtD
Triamcinolone—Body temperature increased—Doxorubicin—urinary bladder cancer	7.8e-05	0.000418	CcSEcCtD
Triamcinolone—Asthenia—Epirubicin—urinary bladder cancer	7.65e-05	0.00041	CcSEcCtD
Triamcinolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	7.57e-05	0.00213	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	7.56e-05	0.00213	CbGpPWpGaD
Triamcinolone—Pruritus—Epirubicin—urinary bladder cancer	7.55e-05	0.000404	CcSEcCtD
Triamcinolone—Dizziness—Methotrexate—urinary bladder cancer	7.54e-05	0.000404	CcSEcCtD
Triamcinolone—BCHE—Metabolism—GSTZ1—urinary bladder cancer	7.45e-05	0.0021	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	7.29e-05	0.00205	CbGpPWpGaD
Triamcinolone—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.27e-05	0.00039	CcSEcCtD
Triamcinolone—Vomiting—Methotrexate—urinary bladder cancer	7.25e-05	0.000388	CcSEcCtD
Triamcinolone—Rash—Methotrexate—urinary bladder cancer	7.19e-05	0.000385	CcSEcCtD
Triamcinolone—Dermatitis—Methotrexate—urinary bladder cancer	7.18e-05	0.000385	CcSEcCtD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	7.16e-05	0.00201	CbGpPWpGaD
Triamcinolone—Headache—Methotrexate—urinary bladder cancer	7.14e-05	0.000383	CcSEcCtD
Triamcinolone—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	7.13e-05	0.00201	CbGpPWpGaD
Triamcinolone—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	7.09e-05	0.00199	CbGpPWpGaD
Triamcinolone—Asthenia—Doxorubicin—urinary bladder cancer	7.08e-05	0.00038	CcSEcCtD
Triamcinolone—BCHE—Metabolism—GSTO2—urinary bladder cancer	7.06e-05	0.00199	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NAT1—urinary bladder cancer	7.06e-05	0.00199	CbGpPWpGaD
Triamcinolone—Dizziness—Epirubicin—urinary bladder cancer	7.05e-05	0.000378	CcSEcCtD
Triamcinolone—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	6.99e-05	0.00197	CbGpPWpGaD
Triamcinolone—Pruritus—Doxorubicin—urinary bladder cancer	6.98e-05	0.000374	CcSEcCtD
Triamcinolone—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	6.95e-05	0.00196	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.95e-05	0.00195	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	6.8e-05	0.00191	CbGpPWpGaD
Triamcinolone—Vomiting—Epirubicin—urinary bladder cancer	6.78e-05	0.000363	CcSEcCtD
Triamcinolone—Nausea—Methotrexate—urinary bladder cancer	6.77e-05	0.000363	CcSEcCtD
Triamcinolone—Rash—Epirubicin—urinary bladder cancer	6.73e-05	0.00036	CcSEcCtD
Triamcinolone—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	6.72e-05	0.00189	CbGpPWpGaD
Triamcinolone—Dermatitis—Epirubicin—urinary bladder cancer	6.72e-05	0.00036	CcSEcCtD
Triamcinolone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	6.71e-05	0.00189	CbGpPWpGaD
Triamcinolone—Headache—Epirubicin—urinary bladder cancer	6.68e-05	0.000358	CcSEcCtD
Triamcinolone—BCHE—Phospholipid metabolism—PTEN—urinary bladder cancer	6.55e-05	0.00184	CbGpPWpGaD
Triamcinolone—Dizziness—Doxorubicin—urinary bladder cancer	6.53e-05	0.00035	CcSEcCtD
Triamcinolone—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	6.48e-05	0.00182	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—UGT2B7—urinary bladder cancer	6.46e-05	0.00182	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	6.4e-05	0.0018	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	6.34e-05	0.00178	CbGpPWpGaD
Triamcinolone—Nausea—Epirubicin—urinary bladder cancer	6.34e-05	0.00034	CcSEcCtD
Triamcinolone—Vomiting—Doxorubicin—urinary bladder cancer	6.28e-05	0.000336	CcSEcCtD
Triamcinolone—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	6.26e-05	0.00176	CbGpPWpGaD
Triamcinolone—Rash—Doxorubicin—urinary bladder cancer	6.22e-05	0.000334	CcSEcCtD
Triamcinolone—Dermatitis—Doxorubicin—urinary bladder cancer	6.22e-05	0.000333	CcSEcCtD
Triamcinolone—Headache—Doxorubicin—urinary bladder cancer	6.18e-05	0.000331	CcSEcCtD
Triamcinolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	6.16e-05	0.00173	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	6.01e-05	0.00169	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	6e-05	0.00169	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—IGFBP3—urinary bladder cancer	5.96e-05	0.00168	CbGpPWpGaD
Triamcinolone—Nausea—Doxorubicin—urinary bladder cancer	5.86e-05	0.000314	CcSEcCtD
Triamcinolone—BCHE—Metabolism—CYP4B1—urinary bladder cancer	5.82e-05	0.00164	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—GSTO2—urinary bladder cancer	5.8e-05	0.00163	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	5.69e-05	0.0016	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	5.6e-05	0.00158	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	5.58e-05	0.00157	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	5.58e-05	0.00157	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	5.56e-05	0.00156	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—SLC19A1—urinary bladder cancer	5.49e-05	0.00155	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	5.44e-05	0.00153	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	5.43e-05	0.00153	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PRSS3—urinary bladder cancer	5.35e-05	0.00151	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	5.3e-05	0.00149	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	5.27e-05	0.00148	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	5.15e-05	0.00145	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	5.15e-05	0.00145	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	5.14e-05	0.00145	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	5.13e-05	0.00144	CbGpPWpGaD
Triamcinolone—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	5e-05	0.00141	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.87e-05	0.00137	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTO2—urinary bladder cancer	4.86e-05	0.00137	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NAT1—urinary bladder cancer	4.86e-05	0.00137	CbGpPWpGaD
Triamcinolone—NR3C1—Adipogenesis—TNF—urinary bladder cancer	4.83e-05	0.00136	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.81e-05	0.00135	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.78e-05	0.00135	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	4.64e-05	0.0013	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SLC19A1—urinary bladder cancer	4.51e-05	0.00127	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	4.45e-05	0.00125	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PRSS3—urinary bladder cancer	4.4e-05	0.00124	CbGpPWpGaD
Triamcinolone—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.38e-05	0.00123	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.29e-05	0.00121	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TYMP—urinary bladder cancer	4.28e-05	0.0012	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	4.25e-05	0.0012	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HDAC4—urinary bladder cancer	4.2e-05	0.00118	CbGpPWpGaD
Triamcinolone—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	4.18e-05	0.00118	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.16e-05	0.00117	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.11e-05	0.00116	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.08e-05	0.00115	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	4e-05	0.00113	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	3.96e-05	0.00111	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NAT2—urinary bladder cancer	3.87e-05	0.00109	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	3.78e-05	0.00106	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PRSS3—urinary bladder cancer	3.68e-05	0.00104	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	3.66e-05	0.00103	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	3.64e-05	0.00102	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.61e-05	0.00101	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.6e-05	0.00101	CbGpPWpGaD
Triamcinolone—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3.49e-05	0.000982	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.49e-05	0.000981	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.48e-05	0.000979	CbGpPWpGaD
Triamcinolone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	3.36e-05	0.000945	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—RRM2—urinary bladder cancer	3.34e-05	0.00094	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—LIG1—urinary bladder cancer	3.33e-05	0.000938	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	3.32e-05	0.000935	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	3.32e-05	0.000933	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.32e-05	0.000933	CbGpPWpGaD
Triamcinolone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.31e-05	0.000932	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.23e-05	0.000908	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	3.19e-05	0.000898	CbGpPWpGaD
Triamcinolone—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	3.18e-05	0.000894	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ENO2—urinary bladder cancer	3.09e-05	0.00087	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—HPGDS—urinary bladder cancer	3.09e-05	0.00087	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.08e-05	0.000865	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTT1—urinary bladder cancer	3e-05	0.000844	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.95e-05	0.000831	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.95e-05	0.000831	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TYMP—urinary bladder cancer	2.95e-05	0.000829	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ESR2—urinary bladder cancer	2.89e-05	0.000814	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.89e-05	0.000813	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.83e-05	0.000796	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.83e-05	0.000795	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.69e-05	0.000758	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.67e-05	0.000751	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NAT2—urinary bladder cancer	2.66e-05	0.000749	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ENO2—urinary bladder cancer	2.54e-05	0.000715	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	2.52e-05	0.000709	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NQO1—urinary bladder cancer	2.49e-05	0.000702	CbGpPWpGaD
Triamcinolone—BCHE—Neuronal System—HRAS—urinary bladder cancer	2.44e-05	0.000685	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.42e-05	0.000681	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—RBX1—urinary bladder cancer	2.41e-05	0.000678	CbGpPWpGaD
Triamcinolone—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.37e-05	0.000668	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.3e-05	0.000647	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.24e-05	0.00063	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	2.23e-05	0.000628	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—JAG1—urinary bladder cancer	2.16e-05	0.000607	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.13e-05	0.000599	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.13e-05	0.000599	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.12e-05	0.000597	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.12e-05	0.000597	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.12e-05	0.000596	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.11e-05	0.000594	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	2.1e-05	0.000591	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTP1—urinary bladder cancer	2.08e-05	0.000585	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.07e-05	0.000581	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.03e-05	0.000572	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	2.03e-05	0.00057	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.01e-05	0.000566	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.94e-05	0.000546	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—TYMS—urinary bladder cancer	1.93e-05	0.000544	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—NCOR1—urinary bladder cancer	1.91e-05	0.000538	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GSTM1—urinary bladder cancer	1.91e-05	0.000538	CbGpPWpGaD
Triamcinolone—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.89e-05	0.000533	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—GPX1—urinary bladder cancer	1.83e-05	0.000515	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—ERCC2—urinary bladder cancer	1.8e-05	0.000506	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—ESR1—urinary bladder cancer	1.75e-05	0.000493	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.75e-05	0.000492	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.72e-05	0.000483	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—MTHFR—urinary bladder cancer	1.69e-05	0.000475	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.65e-05	0.000465	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.61e-05	0.000453	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—PPARG—urinary bladder cancer	1.6e-05	0.00045	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—NCOR1—urinary bladder cancer	1.57e-05	0.000442	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	1.54e-05	0.000432	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERCC2—urinary bladder cancer	1.48e-05	0.000416	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.45e-05	0.000409	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	0.000403	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MTHFR—urinary bladder cancer	1.39e-05	0.000391	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.38e-05	0.00039	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—TERT—urinary bladder cancer	1.38e-05	0.00039	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PPARG—urinary bladder cancer	1.37e-05	0.000385	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.33e-05	0.000374	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—CREBBP—urinary bladder cancer	1.32e-05	0.00037	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.32e-05	0.00037	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.32e-05	0.00037	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.29e-05	0.000362	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—FGFR3—urinary bladder cancer	1.27e-05	0.000357	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.26e-05	0.000354	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.24e-05	0.000348	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.16e-05	0.000327	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	0.000327	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CREBBP—urinary bladder cancer	1.08e-05	0.000304	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTGS2—urinary bladder cancer	1.08e-05	0.000303	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1e-05	0.000283	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—RHOA—urinary bladder cancer	9.78e-06	0.000275	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PPARG—urinary bladder cancer	9.43e-06	0.000265	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—PTEN—urinary bladder cancer	9.4e-06	0.000264	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.3e-06	0.000262	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.3e-06	0.000262	CbGpPWpGaD
Triamcinolone—NR3C1—Gene Expression—MYC—urinary bladder cancer	9.12e-06	0.000257	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—CREBBP—urinary bladder cancer	9.06e-06	0.000255	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—ERBB2—urinary bladder cancer	9.06e-06	0.000255	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	9.02e-06	0.000254	CbGpPWpGaD
Triamcinolone—BCHE—Metabolism—EP300—urinary bladder cancer	8.96e-06	0.000252	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—CDKN1A—urinary bladder cancer	7.74e-06	0.000218	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—PTEN—urinary bladder cancer	7.72e-06	0.000217	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.5e-06	0.000211	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EP300—urinary bladder cancer	7.36e-06	0.000207	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—SRC—urinary bladder cancer	7.16e-06	0.000202	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—PTEN—urinary bladder cancer	6.47e-06	0.000182	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—MYC—urinary bladder cancer	6.42e-06	0.000181	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—EGFR—urinary bladder cancer	6.28e-06	0.000177	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.25e-06	0.000176	CbGpPWpGaD
Triamcinolone—PTGS2—Metabolism—EP300—urinary bladder cancer	6.17e-06	0.000174	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—KRAS—urinary bladder cancer	5.93e-06	0.000167	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.81e-06	0.000164	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.75e-06	0.000162	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.75e-06	0.000162	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.5e-06	0.000155	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.4e-06	0.000152	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	5.08e-06	0.000143	CbGpPWpGaD
Triamcinolone—PTGS2—Disease—HRAS—urinary bladder cancer	5.04e-06	0.000142	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.12e-06	0.000116	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.96e-06	0.000111	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.24e-06	9.11e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.82e-06	7.95e-05	CbGpPWpGaD
Triamcinolone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.69e-06	7.58e-05	CbGpPWpGaD
